UK Markets close in 5 hrs 11 mins

  • FTSE 100

    6,667.98
    -47.44 (-0.71%)
     

  • FTSE 250

    20,584.05
    -209.67 (-1.01%)
     

  • AIM

    1,190.89
    -7.20 (-0.60%)
     

  • GBP/EUR

    1.1227
    -0.0054 (-0.48%)
     

  • GBP/USD

    1.3670
    -0.0060 (-0.4375%)
     

  • BTC-GBP

    23,302.14
    +1,097.60 (+4.94%)
     

  • CMC Crypto 200

    631.34
    +21.35 (+3.50%)
     

  • S&P 500

    3,853.07
    +1.22 (+0.03%)
     

  • DOW

    31,176.01
    -12.37 (-0.04%)
     

  • CRUDE OIL

    51.77
    -1.36 (-2.56%)
     

  • GOLD FUTURES

    1,851.50
    -14.40 (-0.77%)
     

  • NIKKEI 225

    28,631.45
    -125.41 (-0.44%)
     

  • HANG SENG

    29,447.85
    -479.91 (-1.60%)
     

  • DAX

    13,809.30
    -97.37 (-0.70%)
     

  • CAC 40

    5,530.19
    -60.60 (-1.08%)
     
Pharma:

US drug authority approves world's first long-acting HIV regimen

Cabenuva's injectable HIV treatment regimen — which is administered once a month — does not require daily pills

Chelverton UK Dividend Trust plc: Net Asset Value(s)

·1-min read

Chelverton UK Dividend Trust plc (SDVP)
30-Dec-2020 / 12:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

 


Chelverton UK Dividend Trust PLC

 

 

LEI Number: 213800DAF47EJ2HT4P78

 

The Company announces:

 

 

 

 

 

Total Assets (including unaudited revenue reserves at 29/12/2020) of £51.23m

Net Assets (including unaudited revenue reserves at 29/12/2020) of £34.91m

 

 

 

 

 

The Net Asset Value (NAV) at 29/12/2020 was:

 

 

 

 

 

Number of shares in issue:

Per Ordinary share (bid price) - including unaudited current period revenue*

167.42p

20,850,000.00

Per Ordinary share (bid price) - excluding current period revenue* 

167.42p

 

Ordinary share price

164.50p

 

Premium / (Discount) to NAV

(1.75)%

 

Ordinary shares have an undated life

 

 

 

 

 

 

ZDP share

112.54p

14,500,000.00

ZDP share price

112.50p

 

Premium to NAV

(0.04)%

 

ZDP shares are held in a subsidiary and have a redemption date of 30/04/2025

 

 

 

 

 

*Current period undistributed revenue covers the period 01/05/2019 to 29/12/2020

 

 

 

 

 

 

 

 

Chelverton UK Dividend Trust PLC

 

 

LEI Number: 213800DAF47EJ2HT4P78

 

The Company announces:

 

 

 

 

 

Total Assets (including unaudited revenue reserves at 29/12/2020) of £51.23m

Net Assets (including unaudited revenue reserves at 29/12/2020) of £34.91m

 

 

 

 

 

The Net Asset Value (NAV) at 29/12/2020 was:

 

 

 

 

 

Number of shares in issue:

Per Ordinary share (bid price) - including unaudited current period revenue*

167.42p

20,850,000.00

Per Ordinary share (bid price) - excluding current period revenue* 

167.42p

 

Ordinary share price

164.50p

 

Premium / (Discount) to NAV

(1.75)%

 

Ordinary shares have an undated life

 

 

 

 

 

 

ZDP share

112.54p

14,500,000.00

ZDP share price

112.50p

 

Premium to NAV

(0.04)%

 

ZDP shares are held in a subsidiary and have a redemption date of 30/04/2025

 

 

 

 

 

*Current period undistributed revenue covers the period 01/05/2019 to 29/12/2020

 

 

 

 

 

 

 

 

 

LEI Number: 213800DAF47EJ2HT4P78

 

The Company announces:

 

 

 

 

 

Total Assets (including unaudited revenue reserves at 29/12/2020) of £51.23m

Net Assets (including unaudited revenue reserves at 29/12/2020) of £34.91m

 

 

 

 

 

The Net Asset Value (NAV) at 29/12/2020 was:

 

 

 

 

 

Number of shares in issue:

Per Ordinary share (bid price) - including unaudited current period revenue*

167.42p

20,850,000.00

Per Ordinary share (bid price) - excluding current period revenue* 

167.42p

 

Ordinary share price

164.50p

 

Premium / (Discount) to NAV

(1.75)%

 

Ordinary shares have an undated life

 

 

 

 

 

 

ZDP share

112.54p

14,500,000.00

ZDP share price

112.50p

 

Premium to NAV

(0.04)%

 

ZDP shares are held in a subsidiary and have a redemption date of 30/04/2025

 

 

 

 

 

*Current period undistributed revenue covers the period 01/05/2019 to 29/12/2020

 

 

 

 

 

 

 

 

Total Assets (including unaudited revenue reserves at 29/12/2020) of £51.23m

Net Assets (including unaudited revenue reserves at 29/12/2020) of £34.91m

 

 

 

 

 

The Net Asset Value (NAV) at 29/12/2020 was:

 

 

 

 

 

Number of shares in issue:

Per Ordinary share (bid price) - including unaudited current period revenue*

167.42p

20,850,000.00

Per Ordinary share (bid price) - excluding current period revenue* 

167.42p

 

Ordinary share price

164.50p

 

Premium / (Discount) to NAV

(1.75)%

 

Ordinary shares have an undated life

 

 

 

 

 

 

ZDP share

112.54p

14,500,000.00

ZDP share price

112.50p

 

Premium to NAV

(0.04)%

 

ZDP shares are held in a subsidiary and have a redemption date of 30/04/2025

 

 

 

 

 

*Current period undistributed revenue covers the period 01/05/2019 to 29/12/2020

 

 

 

 

 

 

 

ISIN:

GB0006615826, GB00BZ7MQD81

Category Code:

NAV

TIDM:

SDVP

LEI Code:

213800DAF47EJ2HT4P78

OAM Categories:

3.1. Additional regulated information required to be disclosed under the laws of a Member State

Sequence No.:

90603

EQS News ID:

1157922


 

End of Announcement

EQS News Service

show this
show this

Latest stories

  • 'EastEnders' star Natalie Cassidy sick of being 'leaned over' in shops

    The actor said having people get too close is driving her 'mad'.

  • We need to start refreezing the Arctic Ocean as soon as possible to save our megacities

    The climate column: Scientists have been warning about the tipping point of the Arctic icecap melt for decades

  • Mick McCarthy set to take over as Cardiff manager

    The Bluebirds sacked Neil Harris on Thursday after a run of six straight defeats.

  • Pogba is 'big player' for us, says Maguire

    Manchester [UK], January 22 (ANI): Manchester United captain Harry Maguire is impressed with midfielder Paul Pogba's recent performance against Fulham and called him a "big player" of the club.

  • 8 best historical fiction books to read if you loved ‘Bridgerton’

    Make yourself a cuppa and settle in with these thriller novels, romantic tomes, mysteries and more

  • 3 Cheap Dividend Aristocrats to Buy Right Now

    Investors love dividend stocks because they allow you can generate cash flow from your investments without having to sell a single share. Dividends are not guaranteed, and investors learned that the hard way during the pandemic, as many stocks slashed their dividend payments amid the challenging economic conditions. Dividend Aristocrats are income-generating stocks that have not just paid but increased their dividend payments for at least 25 years in a row.

  • Cheltenham would make FA Cup history with Manchester City shock – Michael Duff

    Cheltenham host Manchester City in the FA Cup fourth round on Saturday.

  • Antibody treatment cuts coronavirus infection risk by 80% among care home residents, small study suggests

    One expert has called the results 'very encouraging'.

  • To achieve a real legacy, Biden will have to be more radical – and ready to fight

    To achieve a real legacy, Biden will have to be more radical – and ready to fightThe lesson of the Obama years is that you can have appeasement or transformative progress, but not both

  • ‘Utter joy and acrimony’: How the FA Cup came to define Man United vs Liverpool’s ultimate rivalry

    The bitter rivals meet again in the fourth round with, as Miguel Delaney illustrates, history revealing the best and worst of one of English football’s most iconic fixtures

  • Food subscriptions and online fitness top of Brits' purchases in 2020 amid COVID-19 pandemic

    In an unprecedented year where people found themselves mostly in lockdown and often with reduced income, three in 10 people bought fewer clothes and shoes for themselves and their families.

  • Our justice system is in crisis, so why not abolish jury trials?

    Our justice system is in crisis, so why not abolish jury trials?With a huge backlog of cases due to Covid, it’s a chance to reform archaic and irrelevant court rituals

  • After big hack of U.S. government, Biden enlists 'world class' cybersecurity team

    President Joe Biden is hiring a group of national security veterans with deep cyber expertise, drawing praise from former defense officials and investigators as the U.S. government works to recover from one of the biggest hacks of its agencies attributed to Russian spies. "It is great to see the priority that the new administration is giving to cyber," said Suzanne Spaulding, director of the Defending Democratic Institutions project at the Center for Strategic and International Studies. Cybersecurity was demoted as a policy field under the Trump administration.

  • Worldwide WebRTC Industry to 2026 - Expected to be the Platform of Choice with the Introduction of 5G - ResearchAndMarkets.com

    The "WebRTC Software, Applications, Services, Solutions and Devices Market with Global and Regional Forecasts 2021 - 2026" report has been added to ResearchAndMarkets.com's offering.

  • Ryanair vs the IAG share price: which offers me better value for my 2021 ISA?

    With the airline industry suffering last year due to the pandemic, Jonathan Smith weighs in on why he thinks the IAG share price offers the most value. The post Ryanair vs the IAG share price: which offers me better value for my 2021 ISA? appeared first on The Motley Fool UK.

  • Worldwide Biosurgery Market Growth, Trends and Forecasts (2020-2025) Featuring In-depth Profiles of Baxter, Braun, BD, Johnson & Johnson, Medtronic, Integra Lifesciences and More

    Dublin, Jan. 22, 2021 (GLOBE NEWSWIRE) -- The "Biosurgery Market - Growth, Trends, and Forecasts (2020-2025)" report has been added to ResearchAndMarkets.com's offering. The major factors attributing to the growth of the biosurgery market are increasing geriatric population, rising prevalence of chronic diseases and related surgeries, and a strong focus on R&D leading to the launch of new and advanced products.The global increase in the number of geriatrics population and obese people is likely to lead to numerous health consequences, like greater incidences of ortho and neuro problems. Consequently, the geriatric population and population with obesity are at a higher risk of multiple disorders and diseases.According to the United Nations report in 2017, there were an estimated 962 million people aged 60 or over in the world, comprising 13% of the global population. The population aged 60 or above is growing at a rate of about 3% per year. It was estimated that Europe had the highest percentage of the population aged 60 or over in 2017. Thus, the rise in the geriatric and obese population is acting as a major driver for the growth of the biosurgery market.Key Market TrendsNeurology Segment is Expected to Grow at a Good CAGR in the Application SegmentNeurology and spine-related surgery applications of biosurgery are the major market segments and their growth is driven by a mainly wide application of bone graft substitute products in different biosurgery processes.Another major application segment of biosurgery is the cardiovascular surgery segment that is expected to grow with a positive CAGR in the forecast period, and factors such as the increasing number of cardiac problems in the people across the globe are augmenting the market growth.North America is Expected to Dominate the Market Over the Forecast PeriodNorth America is expected to dominate the overall market, throughout the forecast period. This is due to the increasing number of surgeries, rising obese patients, and increasing geriatric population.In the North America region, the United States holds the largest market share due to factors such as increasing count of geriatrics, along with the growing healthcare industry, which is anticipated to stimulate the demand in this region. Substantial investments by governments to strengthen public healthcare delivery is a key factor augmenting the growth of the market.Competitive LandscapeThe biosurgery market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the prominent players are vigorously making acquisitions with the other companies to consolidate their market positions across the globe. Key Topics Covered 1 INTRODUCTION1.1 Study Deliverables1.2 Study Assumptions1.3 Scope of the Study2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY4 MARKET DYNAMICS4.1 Market Overview4.2 Market Drivers4.2.1 Increasing Geriatric Population4.2.2 Rising Prevalence of Chronic Diseases and Related Surgeries4.2.3 Strong Focus on R&D Leading to the Launch of New and Advanced Products4.3 Market Restraints4.3.1 High Price of Biosurgery Products and Rising Cost of Surgical Procedures4.4 Porter's Five Force Analysis4.4.1 Threat of New Entrants4.4.2 Bargaining Power of Buyers/Consumers4.4.3 Bargaining Power of Suppliers4.4.4 Threat of Substitute Products4.4.5 Intensity of Competitive Rivalry5 MARKET SEGMENTATION5.1 By Product5.1.1 Bone-Graft Substitutes5.1.2 Soft-Tissue Attachments5.1.3 Hemostatic Agents5.1.4 Surgical Sealants and Adhesives5.1.5 Adhesion Barriers5.1.6 Staple Line Reinforcement5.2 By Application5.2.1 Orthopedic Surgery5.2.2 General Surgery5.2.3 Neurological Surgery5.2.4 Cardiovascular Surgery5.2.5 Gynecological Surgery5.2.6 Others5.3 Geography5.3.1 North America5.3.1.1 United States5.3.1.2 Canada5.3.1.3 Mexico5.3.2 Europe5.3.2.1 Germany5.3.2.2 United Kingdom5.3.2.3 France5.3.2.4 Italy5.3.2.5 Spain5.3.2.6 Rest of Europe5.3.3 Asia-Pacific5.3.3.1 China5.3.3.2 Japan5.3.3.3 India5.3.3.4 Australia5.3.3.5 South Korea5.3.3.6 Rest of Asia-Pacific5.3.4 Middle-East and Africa5.3.4.1 GCC5.3.4.2 South Africa5.3.4.3 Rest of Middle-East and Africa5.3.5 South America5.3.5.1 Brazil5.3.5.2 Argentina5.3.5.3 Rest of South America6 COMPETITIVE LANDSCAPE6.1 Company Profiles6.1.1 Baxter International Inc.6.1.2 B. Braun Melsungen AG6.1.3 Becton, Dickinson and Company (C.R. Bard)6.1.4 Johnson & Johnson6.1.5 Medtronic PLC6.1.6 Integra Lifesciences Holdings Corporation6.1.7 CSL Limited6.1.8 CryoLife Inc.6.1.9 Hemostasis LLC6.1.10 Betatech Medical7 MARKET OPPORTUNITIES AND FUTURE TRENDS For more information about this report visit https://www.researchandmarkets.com/r/v1xrv2 Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

  • Pulse Oximeters Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type ; End User and Geography

    The pulse oximeters market was valued at US$ 1,892. 00 million in 2019 and is projected to reach US$ 3,693. 92 million by 2027; it is expected to grow at a CAGR of 8. 6% during 2020–2027. The growth of the market is attributed to increasing prevalence of respiratory diseases and growing preference for remote patient monitoring.New York, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Pulse Oximeters Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type ; End User and Geography" - https://www.reportlinker.com/p06010090/?utm_source=GNW However, the inaccuracies in pulse oximeter readings due to several factors hinders the growth of the market.Pulse oximeter is a non-invasive device used to monitor oxygen saturation level in blood.It is a small, clip-like device that is attached to finger or earlobe.It is mostly used in intensive care, operating, emergency care, and patient at high altitude for assessment of patient’s oxygenation to determine if there is need for supplemental oxygen.Further, pulse oximeters are useful for patients with cardiac problem, respiratory problems, and chronic obstructive pulmonary diseases.Companies operating in the pulse oximeters market are receiving FDA approvals for their innovative products and raising funds for product development, which, in turn, propels the growth of the market.Based on type, the global pulse oximeters market is sub-segmented into fingertip pulse oximeters, handheld pulse oximeters, wrist-worn pulse oximeters, and pediatric pulse oximeters.Fingertip pulse oximeters segment held the largest share of the market in 2019, and it is expected to register a higher CAGR during the forecast period.Based on end user, the global pulse oximeters market is segmented into clinics, hospitals, and others. The clinics segment held the largest share of the market in 2019, and is expected to register the highest CAGR during the forecast period.US Food and Drug Administration (FDA), National Institute of Health (NIH), National Health Agency (ANVISA), European Medical Association are among a few secondary sources referred for preparing this report.Read the full report: https://www.reportlinker.com/p06010090/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

  • Is Now a Good Time to Buy Lemonade?

    It's been an exciting ride for Lemonade (NYSE: LMND) investors. The company went public last summer at an initial public offering (IPO) price of just $29 per share. Lemonade has an exciting market opportunity, but there's no doubt that it's an expensive stock.

  • The housing market caps off a historic year: Morning Brief

    Top news and what to watch in the markets on Friday, January 22, 2021.

  • Intention to take up a Covid-19 vaccine increases with age – ONS

    Around nine in 10 respondents said they would be very likely or fairly likely to have the vaccine, and around one in 20 very or fairly unlikely.